H.C. Wainwright analyst Robert Burns downgraded Prelude Therapeutics to Neutral from Buy with an unchanged price target of $5. The analyst believes the shares are fairly valued following the recent appreciation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRLD:
